Society for Maternal-Fetal Medicine

Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis

Retrieved on: 
Friday, November 10, 2023

Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.

Key Points: 
  • Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.
  • “IriSight™ CNV Analysis provides the first true alternative to CMA,” said Dr. Allan J. Fisher, FACOG, FACMG, Variantyx Medical Director.
  • “Because the entire genome is sequenced, a broader range of chromosomal abnormalities are detected by the test including aneuploidy, unbalanced rearrangements, inversions, deletions/duplications, copy number variants (CNVs), regions of homozygosity and possible uniparental disomy.
  • Variantyx’s proprietary whole genome-based platform enables detection of a wider range of chromosomal abnormalities, not just matching but exceeding the capabilities of traditional CMA.

New Scientific Research Funding Available to Eliminate Pre-Term Deliveries from Preeclampsia

Retrieved on: 
Wednesday, July 5, 2023

MELBOURNE, Fla., July 5, 2023 /PRNewswire/ -- The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research.

Key Points: 
  • MELBOURNE, Fla., July 5, 2023 /PRNewswire/ -- The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research.
  • The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy.
  • Eligible applicants should focus on the current research gaps identified through a 2020 preeclampsia workshop jointly sponsored by the Preeclampsia Foundation and the Society for Maternal Fetal Medicine.
  • The Peter Joseph Pappas Research Grants program adds to the Preeclampsia Foundation's portfolio of research programs including the Vision Grant program for young investigators, and the Preeclampsia Registry, a dynamic database of research participants including preeclampsia and HELLP syndrome survivors, family members, and controls (unaffected individuals).

IAAR site visitors meet with Dominica's Prime Minister Roosevelt Skerrit to discuss collaboration with the American Canadian School of Medicine

Retrieved on: 
Thursday, May 11, 2023

HOUSTON, May 11, 2023 /PRNewswire-PRWeb/ -- Site visitors from the International Agency for Accreditation and Rating (IAAR) met with Dominica's Prime Minister Roosevelt Skerrit and members of his cabinet on Wednesday, May 3, 2023, to discuss areas of cooperation between the Government of Dominica and the American Canadian School of Medicine.

Key Points: 
  • Site visitors from the International Agency for Accreditation and Rating (IAAR) met with Dominica's Prime Minister Roosevelt Skerrit and members of his cabinet on Wednesday, May 3, 2023, to discuss areas of cooperation between the Government of Dominica and the American Canadian School of Medicine.
  • HOUSTON, May 11, 2023 /PRNewswire-PRWeb/ -- Site visitors from the International Agency for Accreditation and Rating (IAAR) met with Dominica's Prime Minister Roosevelt Skerrit and members of his cabinet on Wednesday, May 3, 2023, to discuss areas of cooperation between the Government of Dominica and the American Canadian School of Medicine.
  • Prime Minister Skerrit expressed full support for the American Canadian School of Medicine and its mission to provide high-quality medical education to students in the Commonwealth of Dominica and from other countries.
  • The American Canadian School of Medicine is a leading medical school located in the Commonwealth of Dominica, offering MD degree programs in medicine.

Allegheny Health Network Names Devon M. Ramaeker, MD, Division Chief of Maternal Fetal Medicine

Retrieved on: 
Monday, April 3, 2023

PITTSBURGH, Pa., April 3, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) today announced the appointment of Devon M. Ramaeker, MD, to Division Chief of Maternal Fetal Medicine (MFM) within AHN Women's Institute.

Key Points: 
  • Allegheny Health Network today announced the appointment of Devon M. Ramaeker, MD, to Division Chief of Maternal Fetal Medicine within AHN Women's Institute
    PITTSBURGH, Pa., April 3, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) today announced the appointment of Devon M. Ramaeker, MD , to Division Chief of Maternal Fetal Medicine (MFM) within AHN Women's Institute.
  • Dr. Ramaeker joined AHN in 2022, having previously served as the medical director of MFM at St. Luke's Health System in Kansas City, Missouri.
  • MFM physicians have advanced training in diagnosing and treating complex pregnancies that involve chronic health or genetic conditions, fetal abnormalities, and/or any unforeseen complication to the patient or fetus.
  • Throughout her career, Dr. Ramaeker has advanced an integrated, multidisciplinary approach to managing the complex health needs of this patient population.

The FNIH Announces Results of a New Study Published in The New England Journal of Medicine Showing a Single Dose of Azithromycin Reduced Maternal Sepsis by 35%

Retrieved on: 
Thursday, February 9, 2023

Sepsis is a life-threatening condition caused by the body's extreme response to infection and can lead to organ failure and death.

Key Points: 
  • Sepsis is a life-threatening condition caused by the body's extreme response to infection and can lead to organ failure and death.
  • The study was designed to include 34,000 women in seven low- and middle-income countries who received a single dose of azithromycin or placebo during childbirth.
  • The study included women at study sites located in Bangladesh, the Democratic Republic of Congo, Guatemala, India, Kenya, Pakistan, and Zambia.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health

Research Funding Available for Preeclampsia and Related Pregnancy Disorders

Retrieved on: 
Wednesday, February 8, 2023

SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- Preeclampsia Foundation Canada announced today at the Society for Maternal-Fetal Medicine's (SMFM) 43rd Annual Meeting – The Pregnancy Meeting™ – that applications are now being accepted for its 2023 Vision Grant program.

Key Points: 
  • Preeclampsia Foundation Canada will award two medical research Vision Grants to study preeclampsia and related hypertensive disorders of pregnancy.
  • Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
  • Since 2016, the Preeclampsia Foundation Canada's Vision Grant annual program has invested more than $180,000 in novel research with the goal of supporting new, potentially groundbreaking concepts.
  • "Preeclampsia Foundation Canada looks forward to supporting ambitious and innovative research that will lead to improved maternal and infant health," said Violet Mateljan, President of the Preeclampsia Foundation Canada Board of Directors.

Reach Healthcare Showcases Happy Mama Immersive Maternal Health Experience With New Features at HLTH 2022

Retrieved on: 
Tuesday, November 8, 2022

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reach Healthcare is pleased to announce a new feature within its Happy Mama App called Happy Mama Birthing.

Key Points: 
  • SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reach Healthcare is pleased to announce a new feature within its Happy Mama App called Happy Mama Birthing.
  • This newest feature extends the Happy Mama maternal health reach by delivering the first multi-sensory immersive platform to birthing rooms.
  • Reach Healthcare will feature its Happy Mama immersive experience at HLTH 2022 as part of its three-part multi-sensory experiential exhibition entitled "Beyond the Ordinary," centrally located in the Bassano Rooms (#2602, 2603 and 2604).
  • Reach Healthcare's Happy Mama is reimagining the end-to-end pregnancy experience and ecosystem - whether at home, hospital or in birthing centers.

NYU Langone's Department of Obstetrics & Gynecology Appoints Inaugural Vice Chair for Diversity, Equity, & Inclusion

Retrieved on: 
Tuesday, September 20, 2022

"We are thrilled to have Dr. Clunie join our faculty and the NYU Langone community," says Dana R. Gossett, MD , the Stanley H. Kaplan Professor and Chair of the Department of Obstetrics and Gynecology.

Key Points: 
  • "We are thrilled to have Dr. Clunie join our faculty and the NYU Langone community," says Dana R. Gossett, MD , the Stanley H. Kaplan Professor and Chair of the Department of Obstetrics and Gynecology.
  • An alumnus of Wake Forest School of Medicine, Dr. Clunie completed his residency in obstetrics and gynecology at New York Downtown Hospital.
  • "Diversity is at the center of our responsibility to transform healthcare and lead academic medicine into the future," says Dr. Clunie.
  • "I am excited to join such a well-known obstetrics and gynecology department in a role that recognizes the importance of representation across all areas of medicine, to ensure diversity and inclusion best practices are infused across department activities from recruitment to patient care."

DotLab announces three granted patents for its non-invasive test for endometriosis, DotEndo™

Retrieved on: 
Friday, August 19, 2022

Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.

Key Points: 
  • Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.
  • The inventions embodied in the portfolio of granted patents U.S. Patent No.
  • 11,315,660 B2 also include the company's proprietary machine learning algorithms to detect, predict, diagnose, and monitor the presence or absence of the disease.
  • EMPOWER is the most robust clinical study of its type ever performed, making it an excellent foundation for thecommercial test.

Quest Diagnostics Aims to Close Gaps in Maternal Healthcare with New Obstetrics Test Panel that Includes Hepatitis C Screening

Retrieved on: 
Wednesday, August 17, 2022

SECAUCUS, N.J., Aug. 17, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people easily and reliably for hepatitis C (HCV) with other laboratory tests typically ordered during early pregnancy.

Key Points: 
  • "Our Health Trends research revealed that despite guidelines recommending HCV screening in pregnancy, many people are not receiving the testing they need.
  • Individuals in underserved communities are most likely to experience this gap in care," said Damian "Pat" Alagia, MD, Senior Medical Director, Women's Health, Quest Diagnostics.
  • The reports are based on the Quest Diagnostics database of 60 billion deidentified laboratory test results, believed to be the largest of its kind in healthcare.
  • iii ACOG Practice Advisory: Routine Hepatitis C Virus Screening in Pregnant Individuals (opqic.org) Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB.